Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 11:13 PM
Ignite Modification Date: 2025-12-25 @ 8:49 PM
NCT ID: NCT03308669
Description: All participants who received at least one dose of study drug.
Frequency Threshold: 5
Time Frame: Up To 24 Days
Study: NCT03308669
Study Brief: A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
200 mg Lasmiditan Lasmiditan administered orally, alone 0 None 0 20 8 20 View
Placebo Placebo administered orally, alone 0 None 0 10 3 10 View
Topiramate Alone Topiramate administered orally, alone 0 None 0 30 5 30 View
50 mg Topiramate + 200 mg Lasmiditan Topiramate administered orally, alone, and co-administered with oral lasmiditan 0 None 0 20 8 20 View
50 mg Topiramate + Placebo Topiramate administered orally, alone, and co-administered with oral placebo 0 None 0 10 2 10 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Lip dry SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 20.0 View
Fatigue SYSTEMATIC_ASSESSMENT General disorders MedDRA 20.0 View
Scratch SYSTEMATIC_ASSESSMENT Injury, poisoning and procedural complications MedDRA 20.0 View
Disturbance in attention SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 20.0 View
Dizziness SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 20.0 View
Somnolence SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 20.0 View
Depressed mood SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA 20.0 View
Euphoric mood SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA 20.0 View